Evidence map›Paper›PMID 26045681›Full record

ReviewJournal of ginseng research2015

Review of cases of patient risk associated with ginseng abuse and misuse.

Doo Jin Paik, Chang Ho Lee

Open access · goldAbstract readReview
In one paragraph

Review in Journal of ginseng research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. A Review of the Mechanisms and Risks ofDiseases (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Natural Guardians: Natural Compounds as Radioprotectors in Cancer Therapy.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Current View on How Human Gut Microbiota Mediate Metabolic and Pharmacological Activity ofEndocrine, metabolic & immune disorders drug targets · 2024
    Article
  13. Review
  14. Review
  15. Food science & nutrition · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Doo Jin PaikDepartment of Anatomy and Cell Biology, College of Medicine, Hanyang University, Seoul, Korea.
Chang Ho LeeDepartment of Pharmacology, College of Medicine, Hanyang University, Seoul, Korea.
Hanyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ginseng has long been used as a functional food or therapeutic supplement and it is empirically known to be safe and nontoxic. During recent decades, a number of in vitro and in vivo experiments, as well as human studies have been conducted to prove the safety of various types of ginseng samples and their components. Clinical trials, case reports, and in vitro and in vivo research articles addressing the safety, toxicity, and other adverse events of ginseng application were selected and reviewed. Patient risks associated with ginseng abuse and misuse such as affective disorder, allergy, cardiovascular and renal toxicity, genital organ bleeding, gynecomastia, hepatotoxicity, hypertension, reproductive toxicity, and anticoagulant-ginseng interaction were reviewed and summarized. There are some cases of patient risk associated with ginseng abuse and misuse depending on patients' conditions although further investigation in more cases is required to clarify these issues.

Indexed as

abuse and misusePanax ginsengpatient risk

Identifiers

PMID26045681
PMCPMC4452531
OpenAlexW1965763338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.